These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30239528)

  • 21. Current Status of Biosimilars in Oncology.
    Camacho LH
    Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rise of oncology biosimilars: from process to promise.
    Verrill M; Declerck P; Loibl S; Lee J; Cortes J
    Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
    Jordan JB; Christl L
    Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
    [No Abstract]   [Full Text] [Related]  

  • 27. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
    Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are Biosimilars the Future of Oncology and Haematology?
    Zinzani PL; Dreyling M; Gradishar W; Andre M; Esteva FJ; Boulos S; González Barca E; Curigliano G
    Drugs; 2019 Oct; 79(15):1609-1624. PubMed ID: 31541401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
    Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).
    Fernandes GS; Sternberg C; Lopes G; Chammas R; Gifoni MAC; Gil RA; Araujo DV
    Braz J Med Biol Res; 2018 Jan; 51(3):e7214. PubMed ID: 29340530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.